The University Hospital of Patras has announced a new clinical trial examining the impact of Left Bundle Branch Pacing (LBBP) compared to Right Ventricular Pacing (RVP) on atrial high-rate episodes (AHRE) burden in patients with preserved left ventricular ejection fraction (LVEF). This study is open for participation but has not yet begun recruiting.
Study Details
The trial is funded by the University Hospital of Patras and will involve medical device interventions targeting individuals diagnosed with atrial fibrillation, pacemaker therapy requirements, and atrioventricular block, alongside a preserved LVEF. Researchers aim to determine whether LBBP offers superior outcomes or enhanced device efficiency compared to standard RVP in mitigating AHRE burden.
What Is the Focus of the Trial?
Patients with preserved LVEF undergoing pacemaker therapy often face risks of AHRE, a potential precursor to atrial fibrillation. Left Bundle Branch Pacing has emerged in recent years as a promising alternative to traditional pacing methods. While RVP remains the standard, evidence suggests that LBBP may provide better synchrony and reduce complications related to pacing-induced dyssynchrony.
This trial seeks to fill critical knowledge gaps by rigorously analyzing how LBBP compares to RVP, specifically in AHRE episodes, which are linked to adverse cardiac outcomes.
Expected Impact of the Research
The findings from this study could inform future device development and clinical guidelines for patients requiring pacemakers. Improved pacing methods may benefit patient outcomes, reduce hospitalizations related to atrial arrhythmias, and enhance the quality of life for individuals diagnosed with atrial abnormalities.
The results could also have broader implications for regulatory and clinical adoption of pacing modalities, especially for individuals with preserved ejection fraction who need long-term cardiac rhythm interventions.
FAQ
1. Who can participate in this study?
The trial will include patients diagnosed with atrial fibrillation, atrioventricular block, or individuals needing pacemaker therapy, provided they have preserved left ventricular ejection fraction.
2. What devices are being studied?
The trial compares Right Ventricular Pacing and Left Bundle Branch Pacing devices.
3. What is AHRE burden?
Atrial high-rate episodes (AHRE) refer to instances of rapid atrial rhythms, often detected by device-based diagnostics, which may precede atrial fibrillation or other complications.
4. When will recruitment begin?
Although the trial is currently listed as “not yet recruiting,” updates will be available through its official link.
Conclusion
This clinical trial may redefine pacing practices for patients with preserved LVEF, improving care standards for atrial arrhythmia management. Interested professionals and stakeholders are encouraged to follow study progress for key updates.
Disclaimer
This blog is for informational purposes only and does not constitute legal or medical advice. For professional inquiries, consult with relevant regulatory or clinical experts.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07250529?term=medical+device